Tablets 70mg

 

Leniolisib will be available via the Innovative Medicines Fund (IMF) from 27th March 2025 in line with these recommendations and according to a set of treatment criteria which translates the NICE recommendation into a clinical guide as to use in practice. These treatment criteria can be found on the application form(s) on the Blueteq site.

NHS England will then routinely commission leniolisib in patients 12 years and over with activated phosphoinositide 3-kinase delta syndrome via specialised immunology centres, incorporating these treatment criteria, including those contained within this letter from 90 days after the day of publication of the final guidance.